Amneal Pharmaceuticals Inc (AMRX)
8.365
-0.04
(-0.42%)
USD |
NASDAQ |
Nov 05, 11:20
Amneal Pharmaceuticals Debt to Equity Ratio: -45.47 for June 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
June 30, 2024 | -45.47 |
March 31, 2024 | -41.31 |
December 31, 2023 | 133.49 |
September 30, 2023 | 8.128 |
June 30, 2023 | 8.612 |
March 31, 2023 | 9.279 |
December 31, 2022 | 9.120 |
September 30, 2022 | 9.199 |
June 30, 2022 | 9.904 |
March 31, 2022 | 7.010 |
December 31, 2021 | 7.628 |
September 30, 2021 | 7.862 |
June 30, 2021 | 8.055 |
March 31, 2021 | 8.652 |
Date | Value |
---|---|
December 31, 2020 | 9.288 |
September 30, 2020 | 9.381 |
June 30, 2020 | 9.252 |
March 31, 2020 | 9.856 |
December 31, 2019 | 11.34 |
September 30, 2019 | 12.09 |
June 30, 2019 | 5.746 |
March 31, 2019 | 5.605 |
December 31, 2018 | 5.254 |
September 30, 2018 | 5.737 |
June 30, 2018 | 5.542 |
March 31, 2018 | |
December 31, 2017 | -3.745 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-45.47
Minimum
Jun 2024
133.49
Maximum
Dec 2023
9.962
Average
9.120
Median
Dec 2022
Debt to Equity Ratio Benchmarks
Eli Lilly and Co | 2.185 |
Nutriband Inc | 0.0158 |
NovaBay Pharmaceuticals Inc | -1.128 |
Palatin Technologies Inc | 0.00 |
iBio Inc | 0.0461 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 3.510B |
Total Liabilities (Quarterly) | 3.514B |
Shareholders Equity (Quarterly) | -57.46M |
Current Ratio | 1.333 |
Net Debt Paydown Yield | 1.21% |